Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 7/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 2/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | GOT1 | P17174 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL3143295 | 1.00 | HTR2A (0.98) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL3136309 | 0.99 | KCNH2 (0.97) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL3148898 | 0.99 | KCNH2 (0.97) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL4774002 | 0.99 | HTR2A (1.00) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL29368426 | 0.99 | HTR2A (1.00) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL28028 | 0.99 | HTR2A (1.00) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL4914143 | 0.98 | HTR2A (0.98) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL374870 | 0.98 | HTR2A (0.98) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL5859456 | 0.98 | HTR2A (0.98) | HTR2ADRD2HTR1AKCNH2HTR7 | |
| Ziprasidone SCHEMBL6599516 | 0.98 | HTR2A (0.98) | HTR2ADRD2HTR1AKCNH2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2010-04-01 | — | — | US | claimed |
| CN-117820309-A | Piperazinyl-heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-7745624-B2 | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions | Apotex Pharma Chem Inc. (CA) | 2010-06-29 | — | — | US | disclosed |
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2010-04-01 | — | — | US | disclosed |
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2010-04-01 | — | — | US | disclosed |
| EP-2084156-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Richter Gedeon NYRT (HU) | 2009-08-05 | — | — | EP | disclosed |
| EP-2084156-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Richter Gedeon NYRT (HU) | 2009-08-05 | — | — | EP | disclosed |
| EP-2084156-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Richter Gedeon NYRT (HU) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008062244-A8 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT (HU) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008062244-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062244-A1 | POLYMORPHS OF 5-{2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]-ETHYL}-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2008-05-29 | — | — | WO | disclosed |
| EP-1856115-A1 | PREPARATION OF ACID ADDITION SALTS OF ZIPRASIDONE AND INTERMEDIATES THEREOF BY SOLID PHASE-GAS PHASE REACTIONS | Apotex Pharmachem Inc. (CA) | 2007-11-21 | — | — | EP | disclosed |
| EP-1856115-A1 | PREPARATION OF ACID ADDITION SALTS OF ZIPRASIDONE AND INTERMEDIATES THEREOF BY SOLID PHASE-GAS PHASE REACTIONS | Apotex Pharmachem Inc. (CA) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205947-A1 | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions | APOTEX PHARMACHEM INC. (CA) | 2006-09-14 | — | — | US | disclosed |
| WO-2006094396-A1 | PREPARATION OF ACID ADDITION SALTS OF ZIPRASIDONE AND INTERMEDIATES THEREOF BY SOLID PHASE-GAS PHASE REACTIONS | APOTEX PHARMACHEM INC. (CA) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094396-A1 | PREPARATION OF ACID ADDITION SALTS OF ZIPRASIDONE AND INTERMEDIATES THEREOF BY SOLID PHASE-GAS PHASE REACTIONS | APOTEX PHARMACHEM INC. (CA) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081668-A1 | POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TPH1, TPH2, HTR1A | HTR2A 28/4885DRD2 32/4885HTR2C 17/4885 |
| US-20060205947-A1 | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions | SSRP1, POLR2A, SORD | HTR2A 918/4885DRD2 587/4885HTR2C 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.